Eliminate Price Increases Act of 2016 or the EPI Act

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the manufacturer of a brand name drug from authorizing or commencing the manufacturing, marketing, selling, or distributing of a generic version of the drug from the time the manufacturer is notified by a generic manufacturer that a generic drug application has been submitted until the expiration or forfeiture of the 180-day exclusivity period granted to the generic manufacturer.